NZ540281A - Escitalopram hydrobromide and a method for the preparation thereof - Google Patents

Escitalopram hydrobromide and a method for the preparation thereof

Info

Publication number
NZ540281A
NZ540281A NZ540281A NZ54028103A NZ540281A NZ 540281 A NZ540281 A NZ 540281A NZ 540281 A NZ540281 A NZ 540281A NZ 54028103 A NZ54028103 A NZ 54028103A NZ 540281 A NZ540281 A NZ 540281A
Authority
NZ
New Zealand
Prior art keywords
escitalopram
disorders
escitalopram hydrobromide
disorder
treatment
Prior art date
Application number
NZ540281A
Other languages
English (en)
Inventor
Lawrence Martel
Robert Dancer
Hans Petersen
Peter Ellegaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ540281(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NZ540281A publication Critical patent/NZ540281A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ540281A 2002-12-23 2003-12-18 Escitalopram hydrobromide and a method for the preparation thereof NZ540281A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200202005 2002-12-23
PCT/DK2003/000902 WO2004056791A1 (en) 2002-12-23 2003-12-18 Escitalopram hydrobromide and a method for the preparation thereof

Publications (1)

Publication Number Publication Date
NZ540281A true NZ540281A (en) 2008-07-31

Family

ID=32668635

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ540281A NZ540281A (en) 2002-12-23 2003-12-18 Escitalopram hydrobromide and a method for the preparation thereof

Country Status (32)

Country Link
US (1) US20040167209A1 (cg-RX-API-DMAC7.html)
EP (1) EP1578738B1 (cg-RX-API-DMAC7.html)
JP (2) JP4658613B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050086933A (cg-RX-API-DMAC7.html)
CN (1) CN100349885C (cg-RX-API-DMAC7.html)
AR (1) AR042652A1 (cg-RX-API-DMAC7.html)
AT (1) ATE388947T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003287919B2 (cg-RX-API-DMAC7.html)
BR (1) BR0317623A (cg-RX-API-DMAC7.html)
CA (1) CA2511142A1 (cg-RX-API-DMAC7.html)
CY (1) CY1107451T1 (cg-RX-API-DMAC7.html)
DE (1) DE60319739T2 (cg-RX-API-DMAC7.html)
DK (1) DK1578738T3 (cg-RX-API-DMAC7.html)
EA (1) EA013116B1 (cg-RX-API-DMAC7.html)
EG (1) EG24729A (cg-RX-API-DMAC7.html)
ES (1) ES2298595T3 (cg-RX-API-DMAC7.html)
IL (1) IL169125A0 (cg-RX-API-DMAC7.html)
IS (1) IS2654B (cg-RX-API-DMAC7.html)
ME (1) MEP5808A (cg-RX-API-DMAC7.html)
MX (1) MXPA05005772A (cg-RX-API-DMAC7.html)
MY (1) MY135468A (cg-RX-API-DMAC7.html)
NO (1) NO20053595L (cg-RX-API-DMAC7.html)
NZ (1) NZ540281A (cg-RX-API-DMAC7.html)
PE (1) PE20040924A1 (cg-RX-API-DMAC7.html)
PL (1) PL378275A1 (cg-RX-API-DMAC7.html)
PT (1) PT1578738E (cg-RX-API-DMAC7.html)
RS (1) RS51092B (cg-RX-API-DMAC7.html)
TW (1) TW200501943A (cg-RX-API-DMAC7.html)
UA (1) UA80170C2 (cg-RX-API-DMAC7.html)
UY (1) UY28148A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004056791A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200504109B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
KR20080080094A (ko) * 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
EP2042499B1 (en) * 2006-07-11 2018-06-27 Mitsubishi Tanabe Pharma Corporation Salt of a morpholine compound
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
FR3006594A1 (fr) * 2013-06-11 2014-12-12 Sorin Crm Sas Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
AU2018349284B2 (en) * 2017-10-09 2023-11-16 428 Pharma BV. New salt and solid state forms of escitalopram
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34712A (en) * 1862-03-18 James h
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
WO2000023431A1 (en) * 1998-10-20 2000-04-27 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
HK1043129B (zh) * 1999-10-25 2004-10-21 H‧隆德贝克有限公司 西酞普蘭的製備方法
JP2002020379A (ja) * 2000-05-02 2002-01-23 Sumika Fine Chemicals Co Ltd シタロプラム臭化水素酸塩の結晶およびその結晶化方法
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram
ES2223959T3 (es) * 2000-12-04 2005-03-01 Westfalia Separator Ag Procedimiento de pretratamiento de aceites en bruto y grasas en bruto para la produccion de esteres de acidos grasos.
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
US20050174782A1 (en) * 2003-03-25 2005-08-11 Chapman Leonard T. Flashlight

Also Published As

Publication number Publication date
MXPA05005772A (es) 2005-08-16
ES2298595T3 (es) 2008-05-16
EP1578738B1 (en) 2008-03-12
EG24729A (en) 2010-06-21
CA2511142A1 (en) 2004-07-08
EA013116B1 (ru) 2010-02-26
IL169125A0 (en) 2009-02-11
BR0317623A (pt) 2005-11-29
US20040167209A1 (en) 2004-08-26
MEP5808A (xx) 2010-02-10
DE60319739D1 (de) 2008-04-24
JP2006514952A (ja) 2006-05-18
ZA200504109B (en) 2006-08-30
MY135468A (en) 2008-04-30
AR042652A1 (es) 2005-06-29
KR20050086933A (ko) 2005-08-30
AU2003287919A1 (en) 2004-07-14
JP2011037893A (ja) 2011-02-24
UA80170C2 (en) 2007-08-27
ATE388947T1 (de) 2008-03-15
CY1107451T1 (el) 2012-12-19
RS51092B (sr) 2010-10-31
IS2654B (is) 2010-08-15
JP4658613B2 (ja) 2011-03-23
IS7848A (is) 2005-05-17
PL378275A1 (pl) 2006-03-20
UY28148A1 (es) 2004-09-30
AU2003287919B2 (en) 2009-11-12
DK1578738T3 (da) 2008-06-30
HK1087708A1 (en) 2006-10-20
RS20050487A (sr) 2007-06-04
CN1726202A (zh) 2006-01-25
PE20040924A1 (es) 2004-12-11
EP1578738A1 (en) 2005-09-28
NO20053595L (no) 2005-09-05
PT1578738E (pt) 2008-04-11
EA200501046A1 (ru) 2005-12-29
TW200501943A (en) 2005-01-16
WO2004056791A1 (en) 2004-07-08
DE60319739T2 (de) 2008-07-17
CN100349885C (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
JP2011037893A (ja) 臭化水素酸エスシタロプラム(escitalopramhydrobromide)およびその製造方法
TW201144291A (en) New process for the preparation of dronedarone
SG194021A1 (en) Reductive amination process for preparation of dronedarone using amine intermediary compound
BR9917368B1 (pt) mÉtodo para preparaÇço de citalopram.
SK13662002A3 (sk) Spôsob prípravy citalopramu, antidepresívny farmaceutický prostriedok s obsahom citalopramu a medziprodukt
ZA200110133B (en) Process for the preparation of pure citalopram.
EA005491B1 (ru) Способ получения циталопрама
US8288568B2 (en) Process for the preparation of escitalopram
HK1087708B (en) Escitalopram hydrobromide and a method for the preparation thereof
US20050137255A1 (en) Crystalline escitalopram hydrobromide and methods for preparing the same
EP1485367B1 (en) Purified citalopram salts
EP2017271A1 (en) Process for the preparation of escitalopram
WO2003042202A1 (en) Isobenzofuran derivatives
KR20140020981A (ko) 메실화에 의한 드로네다론의 제조방법

Legal Events

Date Code Title Description
AVOD Application void
PSEA Patent sealed
RENW Renewal (renewal fees accepted)